CR20170102A - Nuevos activadores de la guanilato ciclasa soluble y su uso - Google Patents
Nuevos activadores de la guanilato ciclasa soluble y su usoInfo
- Publication number
- CR20170102A CR20170102A CR20170102A CR20170102A CR20170102A CR 20170102 A CR20170102 A CR 20170102A CR 20170102 A CR20170102 A CR 20170102A CR 20170102 A CR20170102 A CR 20170102A CR 20170102 A CR20170102 A CR 20170102A
- Authority
- CR
- Costa Rica
- Prior art keywords
- soluble
- guanilate
- cycling
- new activators
- activators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
La invención se refiere a activadores de la guanilato ciclasa soluble y su uso en composiciones farmacéuticas, principalmente composiciones oftálmicas administradas por vía tópica. Las composiciones farmacéuticas son útiles para reducir la presión intraocular en los animales de las especies de mamíferos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052537P | 2014-09-19 | 2014-09-19 | |
| PCT/IB2015/057219 WO2016042536A1 (en) | 2014-09-19 | 2015-09-18 | Novel soluble guanylate cyclase activators and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20170102A true CR20170102A (es) | 2017-07-17 |
Family
ID=54238488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20170102A CR20170102A (es) | 2014-09-19 | 2015-09-18 | Nuevos activadores de la guanilato ciclasa soluble y su uso |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9938260B2 (es) |
| EP (1) | EP3194384A1 (es) |
| JP (3) | JP6678656B2 (es) |
| KR (1) | KR20170054508A (es) |
| CN (1) | CN106687456B (es) |
| AU (1) | AU2015319724B2 (es) |
| BR (1) | BR112017005660A2 (es) |
| CA (1) | CA2961745A1 (es) |
| CL (1) | CL2017000640A1 (es) |
| CO (1) | CO2017002506A2 (es) |
| CR (1) | CR20170102A (es) |
| DO (1) | DOP2017000073A (es) |
| EA (1) | EA033697B1 (es) |
| IL (1) | IL251094A0 (es) |
| MA (1) | MA40583A (es) |
| MX (1) | MX2017003621A (es) |
| PE (1) | PE20170937A1 (es) |
| PH (1) | PH12017500481A1 (es) |
| SG (1) | SG11201701915TA (es) |
| WO (1) | WO2016042536A1 (es) |
| ZA (1) | ZA201701835B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201606269WA (en) | 2014-02-06 | 2016-09-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
| AU2015316796A1 (en) | 2014-09-19 | 2017-03-30 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as Bub1 inhibitors |
| CN106687456B (zh) * | 2014-09-19 | 2019-12-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 可溶性鸟苷酸环化酶活化剂及它们的用途 |
| CN109890379A (zh) | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品 |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| US20210052528A1 (en) | 2018-04-30 | 2021-02-25 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| BR112020022340A2 (pt) | 2018-05-15 | 2021-02-02 | Bayer Aktiengesellschaft | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas |
| EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
| WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602143A (en) | 1994-12-08 | 1997-02-11 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors |
| ES2421206T3 (es) * | 2006-11-09 | 2013-08-29 | Alcon Research, Ltd. | Matriz de polímero insoluble en agua para el suministro de fármaco |
| PE20091258A1 (es) | 2007-12-03 | 2009-09-12 | Smithkline Beecham Corp | Derivados de piridina como activadores de la guanilato ciclasa soluble |
| WO2010015653A1 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| MX2011008952A (es) * | 2009-02-26 | 2011-09-27 | Merck Sharp & Dohme | Activadores de guanilato ciclasa solubles. |
| DE102009012314A1 (de) | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
| JP5636296B2 (ja) | 2011-01-20 | 2014-12-03 | 公益財団法人微生物化学研究会 | 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体 |
| CN106687456B (zh) * | 2014-09-19 | 2019-12-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 可溶性鸟苷酸环化酶活化剂及它们的用途 |
-
2015
- 2015-09-18 CN CN201580050717.XA patent/CN106687456B/zh active Active
- 2015-09-18 AU AU2015319724A patent/AU2015319724B2/en active Active
- 2015-09-18 US US15/509,895 patent/US9938260B2/en active Active
- 2015-09-18 CR CR20170102A patent/CR20170102A/es unknown
- 2015-09-18 WO PCT/IB2015/057219 patent/WO2016042536A1/en active Application Filing
- 2015-09-18 JP JP2017515074A patent/JP6678656B2/ja active Active
- 2015-09-18 SG SG11201701915TA patent/SG11201701915TA/en unknown
- 2015-09-18 MA MA040583A patent/MA40583A/fr unknown
- 2015-09-18 MX MX2017003621A patent/MX2017003621A/es unknown
- 2015-09-18 PE PE2017000478A patent/PE20170937A1/es unknown
- 2015-09-18 BR BR112017005660A patent/BR112017005660A2/pt not_active Application Discontinuation
- 2015-09-18 CA CA2961745A patent/CA2961745A1/en not_active Abandoned
- 2015-09-18 KR KR1020177010181A patent/KR20170054508A/ko not_active Application Discontinuation
- 2015-09-18 EA EA201790655A patent/EA033697B1/ru not_active IP Right Cessation
- 2015-09-18 EP EP15772026.9A patent/EP3194384A1/en not_active Withdrawn
-
2017
- 2017-03-12 IL IL251094A patent/IL251094A0/en unknown
- 2017-03-14 ZA ZA2017/01835A patent/ZA201701835B/en unknown
- 2017-03-14 PH PH12017500481A patent/PH12017500481A1/en unknown
- 2017-03-16 CL CL2017000640A patent/CL2017000640A1/es unknown
- 2017-03-16 CO CONC2017/0002506A patent/CO2017002506A2/es unknown
- 2017-03-16 DO DO2017000073A patent/DOP2017000073A/es unknown
-
2018
- 2018-03-05 US US15/911,797 patent/US10472350B2/en active Active
-
2020
- 2020-03-02 JP JP2020035272A patent/JP6908747B2/ja active Active
-
2021
- 2021-06-30 JP JP2021109106A patent/JP2021155450A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA033697B1 (ru) | 2019-11-18 |
| JP6908747B2 (ja) | 2021-07-28 |
| DOP2017000073A (es) | 2017-04-16 |
| US9938260B2 (en) | 2018-04-10 |
| BR112017005660A2 (pt) | 2017-12-19 |
| JP2017527602A (ja) | 2017-09-21 |
| AU2015319724A1 (en) | 2017-04-06 |
| JP2020105189A (ja) | 2020-07-09 |
| CN106687456B (zh) | 2019-12-03 |
| JP6678656B2 (ja) | 2020-04-08 |
| ZA201701835B (en) | 2018-12-19 |
| CL2017000640A1 (es) | 2017-10-06 |
| PH12017500481A1 (en) | 2017-08-07 |
| MA40583A (fr) | 2016-03-24 |
| JP2021155450A (ja) | 2021-10-07 |
| CN106687456A (zh) | 2017-05-17 |
| US20180194756A1 (en) | 2018-07-12 |
| WO2016042536A1 (en) | 2016-03-24 |
| CA2961745A1 (en) | 2016-03-24 |
| AU2015319724B2 (en) | 2018-05-10 |
| CO2017002506A2 (es) | 2017-07-28 |
| EP3194384A1 (en) | 2017-07-26 |
| SG11201701915TA (en) | 2017-04-27 |
| MX2017003621A (es) | 2017-07-14 |
| US10472350B2 (en) | 2019-11-12 |
| PE20170937A1 (es) | 2017-07-13 |
| IL251094A0 (en) | 2017-04-30 |
| EA201790655A1 (ru) | 2017-08-31 |
| KR20170054508A (ko) | 2017-05-17 |
| US20170305888A1 (en) | 2017-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000073A (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| ECSP17078433A (es) | Composiciones de ácido obeticólico y métodos de uso | |
| NI201700096A (es) | Derivados de 4h-pirrol[3, 2-c]piridin-4-ona | |
| ECSP17081744A (es) | Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| NI201400079A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| ECSP16074478A (es) | Compuestos novedosos | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| DOP2017000058A (es) | Derivados de tetrahidroquinolina como inhibidores del bromodominio | |
| CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 | |
| CO2017002963A2 (es) | Espiro-tiazolonas | |
| UY35665A (es) | ?compuestos de carboxamida, proceso de preparación y su uso como nematicidas?. | |
| UY36958A (es) | Compuestos para administración intracelular | |
| CR20140051A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| CR20180110A (es) | Libobactina para uso en el tratamiento de la mastitis bovina | |
| GT201500116A (es) | Mètodo para preparar derivados de feniloximetil-nitro-imidazol y su uso del mismo |